$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000105572623000030 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$226.0K	$114.9K
YoY Change	-71.19%	-42.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.52M	$13.89M
YoY Change	-72.09%	-12.93%
% of Gross Profit
Research & Development	$23.74M	$30.18M
YoY Change	-57.95%	-46.09%
% of Gross Profit
Depreciation & Amortization	$766.6K	$707.4K
YoY Change	-28.43%	-23.89%
% of Gross Profit
Operating Expenses	$37.27M	$44.07M
YoY Change	-64.48%	-38.74%
Operating Profit	-$37.04M	-$43.95M
YoY Change	-64.43%	-38.73%
Interest Expense	$313.5K	$313.5K
YoY Change	-107.2%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$1.428M	-$2.426M
YoY Change	46715.31%	1480.57%
Pretax Income	-$35.53M	-$40.65M
YoY Change	-67.25%	-47.15%
Income Tax
% Of Pretax Income
Net Earnings	-$35.50M	-$40.60M
YoY Change	-67.28%	-48.67%
Net Earnings / Revenue	-15709.98%	-35321.86%
Basic Earnings Per Share	-$0.13	-$0.16
Diluted Earnings Per Share	-$0.13	-$0.16
COMMON SHARES
Basic Shares Outstanding	262.7M shares	260.1M shares
Diluted Shares Outstanding	264.4M shares	258.4M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$194.9M	$223.8M
YoY Change	-44.01%	-37.91%
Cash & Equivalents	$52.71M	$28.24M
Short-Term Investments	$142.2M	$195.5M
Other Short-Term Assets	$3.243M	$5.110M
YoY Change	-94.28%	-84.04%
Inventory
Prepaid Expenses
Receivables	$5.950K	$73.30K
Other Receivables	$5.110M	$4.962M
Total Short-Term Assets	$203.3M	$233.9M
YoY Change	-51.16%	-41.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.304M	$6.983M
YoY Change	-76.76%	-58.18%
Goodwill	$10.51M	$10.51M
YoY Change		0.0%
Intangibles	$0.00	$2.048M
YoY Change		-18.08%
Long-Term Investments	$2.781M	$2.624M
YoY Change	14.19%	-22.12%
Other Assets	$666.9K	$652.5K
YoY Change	-13.41%	-48.77%
Total Long-Term Assets	$29.75M	$32.69M
YoY Change	-31.15%	-28.33%
TOTAL ASSETS
Total Short-Term Assets	$203.3M	$233.9M
Total Long-Term Assets	$29.75M	$32.69M
Total Assets	$233.0M	$266.6M
YoY Change	-49.27%	-40.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.36M	$26.17M
YoY Change	-90.26%	-33.79%
Accrued Expenses	$21.12M	$8.376M
YoY Change	64.22%	-42.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.71M	$16.39M
YoY Change
Total Short-Term Liabilities	$51.93M	$55.15M
YoY Change	-60.38%	-7.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$11.70M	$12.19M
YoY Change	-17.07%
Total Long-Term Liabilities	$11.70M	$12.19M
YoY Change	-61.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.93M	$55.15M
Total Long-Term Liabilities	$11.70M	$12.19M
Total Liabilities	$63.67M	$67.37M
YoY Change	-60.63%	-25.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.600B	-$1.500B
YoY Change		15.38%
Common Stock	$268.1K	$262.7K
YoY Change		15.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$169.4M	$199.2M
YoY Change
Total Liabilities & Shareholders Equity	$233.0M	$266.6M
YoY Change	-49.27%	-40.16%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$35.50M	-$40.60M
YoY Change	-67.28%	-48.67%
Depreciation, Depletion And Amortization	$766.6K	$707.4K
YoY Change	-28.43%	-23.89%
Cash From Operating Activities	-$32.31M	-$36.66M
YoY Change	-36.05%	-40.75%
INVESTING ACTIVITIES
Capital Expenditures	$23.92K	$297.0K
YoY Change	-103.34%
Acquisitions
YoY Change
Other Investing Activities	$53.93M	$19.30M
YoY Change	-662.55%	-9.54%
Cash From Investing Activities	$53.91M	$19.00M
YoY Change	-623.16%	-10.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.883M	-$424.7K
YoY Change	-93.29%	-101.49%
NET CHANGE
Cash From Operating Activities	-32.31M	-$36.66M
Cash From Investing Activities	53.91M	$19.00M
Cash From Financing Activities	2.883M	-$424.7K
Net Change In Cash	24.47M	-$18.09M
YoY Change	-236.79%	49.09%
FREE CASH FLOW
Cash From Operating Activities	-$32.31M	-$36.66M
Capital Expenditures	$23.92K	$297.0K
Free Cash Flow	-$32.34M	-$36.96M
YoY Change	-35.08%	-40.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-14888
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0969592
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	660 W. Germantown Pike
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Plymouth Meeting
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19462
CY2023Q1	dei	City Area Code CityAreaCode	267
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	440-4200
CY2023Q1	dei	Security12b Title Security12bTitle	COMMON STOCK, $0.001 PAR VALUE
CY2023Q1	dei	Trading Symbol TradingSymbol	INO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	262740113	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28238152	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46329359	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	195513005	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	206669397	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	73304	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1701726	usd
CY2023Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	4961802	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	10036490	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4914313	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50130481	usd
CY2023Q1	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	195853	usd
CY2022Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	375227	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	233896429	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	315242680	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6983305	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7727997	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2623781	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	2007142	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2047778	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2129861	usd
CY2023Q1	us-gaap	Goodwill Goodwill	10513371	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10513371	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9865543	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10228207	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	652517	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	684044	usd
CY2023Q1	us-gaap	Assets Assets	266582724	usd
CY2022Q4	us-gaap	Assets Assets	348533302	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24752171	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	79686885	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1417274	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1220439	usd
CY2023Q1	ino	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	5795846	usd
CY2022Q4	ino	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	10594073	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2579949	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2803973	usd
CY2023Q1	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	4121989	usd
CY2022Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	2475031	usd
CY2023Q1	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	89007	usd
CY2022Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	87673	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	16394841	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	55151077	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96868074	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	16614840	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12185919	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12655586	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32046	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	32046	usd
CY2023Q1	us-gaap	Liabilities Liabilities	67369042	usd
CY2022Q4	us-gaap	Liabilities Liabilities	126170546	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	262738	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	253090	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1728030842	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1710656191	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1528497101	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1487847784	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-582797	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-698741	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	199213682	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	222362756	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	266582724	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348533302	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114943	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	199074	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30176511	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55978611	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13890610	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15953458	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	44067121	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	71932069	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-43952178	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-71732995	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	2207171	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	669814	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	313488	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	313488	usd
CY2023Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	616639	usd
CY2022Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-537728	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	3218215	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4840641	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2425676	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-153468	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-40649317	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-76908506	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2165213	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40649317	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79073719	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258437714	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	258437714	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	218940693	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	218940693	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40649317	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79073719	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1918	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6555	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	117862	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169097	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-40533373	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-79249371	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	222362756	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-424704	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3809003	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40649317	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	117862	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1918	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	199213682	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	399669421	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29364538	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-942521	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7711151	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79073719	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169097	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6555	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	355085002	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40649317	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-79073719	usd
CY2023Q1	us-gaap	Depreciation Depreciation	707378	usd
CY2022Q1	us-gaap	Depreciation Depreciation	929383	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82083	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126770	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	362664	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	319586	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3809003	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7711151	usd
CY2023Q1	ino	Non Cash Interest Income Expense NonCashInterestIncomeExpense	219999	usd
CY2022Q1	ino	Non Cash Interest Income Expense NonCashInterestIncomeExpense	219999	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1159083	usd
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-125810	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	-2425676	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	-318684	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-334297	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-157666	usd
CY2023Q1	ino	Gain Loss On Remeasurement Of Equity Method Investment GainLossOnRemeasurementOfEquityMethodInvestment	0	usd
CY2022Q1	ino	Gain Loss On Remeasurement Of Equity Method Investment GainLossOnRemeasurementOfEquityMethodInvestment	165215	usd
CY2023Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	616639	usd
CY2022Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-537728	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2165213	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	3218215	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4840641	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6703110	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-541248	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39324542	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7075934	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-31527	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-151999	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40737879	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9000559	usd
CY2023Q1	ino	Increase Decrease In Accrued Clinical Trial Expense IncreaseDecreaseInAccruedClinicalTrialExpense	-4798227	usd
CY2022Q1	ino	Increase Decrease In Accrued Clinical Trial Expense IncreaseDecreaseInAccruedClinicalTrialExpense	1501489	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9963	usd
CY2023Q1	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-693691	usd
CY2022Q1	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-624673	usd
CY2023Q1	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	1648292	usd
CY2022Q1	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	723550	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-14826	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36664478	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61882102	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	80431174	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	99722697	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	93657050	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	123055048	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	296983	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6071000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	usd
CY2022Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	1999998	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18999893	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21332353	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29364538	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83812	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	424704	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1026333	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-424704	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28422017	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1918	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6555	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18091207	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12134287	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46329359	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71143778	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28238152	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59009491	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	330779	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	533487	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	533487	usd
CY2023Q1	ino	Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement	14000000	usd
CY2022Q1	ino	Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement	0	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company’s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO's lead candidates are focused on diseases associated with HPV. In October 2022 and February 2023, INOVIO announced data from the first and second cohorts, respectively, of its Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, Indiana University, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for the Ebola virus; HPV-related precancers, including cervical, vulvar and anal dysplasia; HPV-related cancers, including head & neck; other HPV-related disorders, such as RRP; and glioblastoma (GBM).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div>
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40600000	usd
CY2023Q1	ino	Working Capital WorkingCapital	178700000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	223800000	usd
CY2023Q1	ino	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	845000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	201958124	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	71009	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6516128	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	195513005	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	216450597	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21231	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9802431	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	206669397	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	300	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	20000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	2400000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	339000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	3200000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4800000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	24	position
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6500000	usd
CY2023Q1	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	0	usd
CY2022Q4	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	30000000	usd
CY2023Q1	ino	Prepaid Manufacturing Expenses Current PrepaidManufacturingExpensesCurrent	565072	usd
CY2022Q4	ino	Prepaid Manufacturing Expenses Current PrepaidManufacturingExpensesCurrent	1401028	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4349241	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	18729453	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4914313	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50130481	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	11194396	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	19862487	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7607673	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	12574921	usd
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	44000000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	5950102	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	3249477	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24752171	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	79686885	usd
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	10513371	usd
CY2023Q1	us-gaap	Goodwill Goodwill	10513371	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	10513371	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10513371	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9150000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7102222	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2047778	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10473761	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8343900	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2129861	usd
CY2023Q1	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	19663371	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7102222	usd
CY2023Q1	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	12561149	usd
CY2022Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	20987132	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8343900	usd
CY2022Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	12643232	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	127000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	190000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	253000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	253000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	253000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	253000	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	262739126	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	262739126	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	253091319	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20462532	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21305035	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10500000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
CY2021	ino	Collaborative Agreement Amended Amount CollaborativeAgreementAmendedAmount	13600000	usd
CY2023Q1	ino	Collaborative Agreement Awarded Exercised Amount CollaborativeAgreementAwardedExercisedAmount	3300000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3136000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3050000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3063000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3139000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2526000	usd
CY2023Q1	ino	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4223000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19137000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4371000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14766000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2580000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12186000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.086
CY2023Q1	us-gaap	Lease Cost LeaseCost	840000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	830000	usd
CY2019Q4	ino	Lessee Operating Lease Number Of Agreements To Sublease LesseeOperatingLeaseNumberOfAgreementsToSublease	2	agreement

Files In Submission

Name	View Source	Status
0001055726-23-000030-index-headers.html	Edgar Link	pending
0001055726-23-000030-index.html	Edgar Link	pending
0001055726-23-000030.txt	Edgar Link	pending
0001055726-23-000030-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ino-20230331.htm	Edgar Link	pending
ino-20230331.xsd	Edgar Link	pending
ino-20230331_g1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ino-20230331_def.xml	Edgar Link	unprocessable
ino-20230331_cal.xml	Edgar Link	unprocessable
ino-20230331_lab.xml	Edgar Link	unprocessable
ino-20230331_pre.xml	Edgar Link	unprocessable
ino-20230331_htm.xml	Edgar Link	completed
ino-3312310qex312.htm	Edgar Link	pending
ino-33123x10qex311.htm	Edgar Link	pending
ino-33123x10qex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2023 Q2 Form 10-Q Financial Statement

#000105572623000030 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2023 Q2 Form 10-Q Financial Statement

#000105572623000030 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino